TLR agonist shows the curative effect of single and compound prescription

At the SITC annual meeting today, Professor Kirkwood of the University of Pittsburgh reported the second phase clinical results of checkmate pharmaceutical's TLR9 agonist cmp-001 alone or in combination with drug K in patients with drug-resistant Diablo The response rate of the compound group was 25%, including 6 CR patients, and the median PFS of 28 patients was estimated to be over 16.9 months (not yet reached) There were 5 PR cases in 24 patients in the unilateral group, but the persistence was worse than that in the compound group The combination of cmp-001 and O will be announced at the annual meeting tomorrow The preliminary results of this trial have been disclosed The combination of two drugs produces 71% significant pathological response (MPR), and 13 of the 15 patients respond completely (PCR) No patient delayed surgery because of the combination Diablo is a relatively rare solid tumor, even though it was a highly lethal malignant tumor 10 years ago Bob Marley, a famous singer, died of Diablo in the 1980s It is said that his last words were "money can't buy life" to his son Ziggy However, with the successive marketing of BRAF inhibitors, CTLA4 and PD-1 drugs, the 5-year survival rate of advanced Diablo has exceeded 50%, and ordinary people can already buy life with money The first ordinary college student who took part in the clinical trial of yevoy was unable to walk at that time, but after using yevoy, he got married and had children, and ran several marathons Although this is a great technological progress, there are still patients who do not respond to existing drugs or have drug resistance problems, so even in the highly immunogenic Diablo, adjuvant therapy is still needed to expand the response population.